Physician profile
Thomas Delaney
NPI 1225033269
$579.34
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $118 · 2021: $106.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $191.69 | 2019-2021 | |
| Ucb, INC. | $119.25 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.03 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.19 | 2019 | |
| Genzyme Corporation | $35.54 | 2019 | |
| Amgen INC. | $20.70 | 2021 | |
| Shire North American Group INC | $20.00 | 2019 | |
| Shionogi INC | $16.12 | 2019 | |
| Celgene Corporation | $13.88 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.14 | 2021 | |
| Braintree Laboratories, INC. | $12.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Delaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.